Onasemnogene abeparvovec was developed to treat spinal muscular atrophy, a disease linked to a mutation in the survival motor neuron 1 (SMN1) gene on chromosome 5q and diagnosed predominantly in young children that causes progressive loss of muscle function and frequently death. The medication is administered as an intravenous infusion.<\/p>\n
ITVISMA (onasemnogene abeparvovec-brve) suspension, for intrathecal injection Initial U.S. Approval: 2025<\/strong><\/p>\n ITVISMA (onasemnogene abeparvovec-brve) may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n Named-patient import facilitator contact details<\/strong> Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n Note:<\/strong><\/em> ITVISMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in SMN1 gene. Under the CDSCO Named Patient Program, Indian patients can legally import breast cancer drugs that are FDA-approved in other countries but not commercially marketed in India.<\/p>\nIs ITVISMA (onasemnogene abeparvovec-brve) in India?<\/h4>\n
How to get ITVISMA injection delivered in India?<\/h4>\n
Who can help source ITVISMA injection in India legally?<\/h4>\n
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"\n\n
\n Brand Name:<\/strong><\/td>\n ITVISMA<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n onasemnogene abeparvovec-brve injection<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n Each single-dose vial contains 1.2 \u00d7 1014 vg of onasemnogene abeparvovec in 3 mL of suspension. ITVISMA has a nominal concentration of 4 \u00d71013 vg\/mL, and each vial contains an extractable volume of not less than 3 mL.<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Novartis Gene Therapies<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n